| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. | Arthritis Rheum | 2003 | 1.79 |
| 2 | Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. | J Rheumatol | 2007 | 1.63 |
| 3 | Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. | Arthritis Res Ther | 2005 | 1.61 |
| 4 | Biologic therapies in the spondyloarthritis: new opportunities, new challenges. | Curr Opin Rheumatol | 2003 | 1.04 |
| 5 | The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders. | J Rheumatol | 2009 | 0.77 |
| 6 | Multicenter Clinical Randomized Controlled Trial Evaluation of an Implant System Designed for Enhanced Primary Stability. | Int J Oral Maxillofac Implants | 2016 | 0.75 |